How the body handles sugar in women with polyendocrine metabolic ovarian syndrome
Compares blood changes after a sugar drink in women with and without PMOS.
Key facts
- Who runs it
- University of Zurich
- Where
- Zurich, SwitzerlandSee the site
- Trial code
- Registry title
- Assessment of Metabolic Changes in Response to Glcuose Intake in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS)
- Status
- Not yet recruiting
- People taking part
- 40 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 30 Jul 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Oral Clucose Tolerance Test (oGTT)
- Record updated
- 7 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18-35 with polycystic ovary syndrome (PMOS/PCOS), and for women of the same age without it as a comparison group.
- Age
- 18 to 35 years
- Sex
- Women only
- Disease stage
- One group has PCOS confirmed by the Rotterdam criteria, phenotype A: irregular or missing ovulation, signs of high male hormones, and polycystic ovaries on ultrasound. The comparison group has regular periods (21 to 35 days) for the last 3 months.
- Earlier treatment
- No systemic hormonal contraceptives in the last 3 months. A levonorgestrel-releasing intrauterine device is allowed.
- Biomarker or test result
- Biochemical or clinical signs of high male hormones (androgens) in the PCOS group.
Main reasons for not taking part
- Hormonal contraceptives in the last 3 months (except a levonorgestrel-releasing intrauterine device)
- Pregnancy or breastfeeding, or birth within the last 12 months
- Heart or blood vessel disease, lung disease, or blood pressure above 160/90 mm/Hg at rest
- Mental disorder, eating disorder in the last 5 years, or epileptic seizure
- Regular medication other than thyroxine, daily nicotine, vegan diet, or alcohol above 12 g per day
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Age: 18-35 years
- Body weight (BMI): between BMI 18.5-39.9 kg/m2
- Ability to consent and to provide written informed consent
- CG: History of regular MCs (21 to 35 days) 3 months prior to study enrollment
- PCOS-G: Existing or new established diagnosis of PCOS. Diagnosis is verified in accordance with the ESHRE/ASRM Rotterdam consensus (2003)23, phenotype A (hyperandrogenism, oligo-/anovulation, and polycystic ovarian morphology). PCOS is diagnosed when at least the following three criteria are present, after exclusion of other etiologies:; Oligo- or anovulation; Clinical and/or biochemical signs of hyperandrogenism; Polycystic ovaries on ultrasound (≥12 follicles per ovary measuring 2-9 mm in diameter and/or ovarian volume >10 mL)
Who cannot take part
- Use of systemic hormonal contraceptives within the last 3 months prior to study enrollment. Use of levonorgestrel-releasing intrauterine devices is permitted; all other hormonal contraceptive methods are excluded
- regular use of medication other than thyroxine
- surgery less than 1 month ago
- having given birth within 12 months before the start of the study
- CG: A clinically diagnosed or history of a menstrual disorder (e.g., polycystic ovarian syndrome (PCOS), premenstrual dysphoric disorder (PMDD) or amenorrhea)
- A clinically diagnosed mental disorder (e.g. major depression, anxiety disorder)
- history of epileptic seizure
- history of or current manic or psychotic episode
- existing/current eating disorders (bulimia nervosa, anorexia nervosa) within the past 5 years
- currently or history of (regular) consumption of illegal drugs within the last year
- known diseases of the cardiovascular system
- arterial hypertension above 160/90 mm/Hg at rest
- known pulmonary diseases
- Arthritis and rheumatic diseases and conditions
- Hematologic diseases
- inability to communicate adequately in speech
- inability to follow instructions
- alcohol consumption as equivalent doses of more than 12 g of pure alcohol per day
- vegan diet
- daily nicotine consumption
- pregnancy or breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 35 years old?
Where in Switzerland
- University Hospital ZurichZurich, SwitzerlandContact: Jens Stepan, MD, PhDNot yet recruiting
About the trial
What the trial wants to find out
Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome (PCOS), is a common endocrine and metabolic condition affecting women of reproductive age. It is associated with hormonal imbalances, irregular menstrual cycles, elevated androgen levels, and metabolic disturbances such as insulin resistance. These metabolic changes can increase the risk of type 2 diabetes and cardiovascular disease.
Read full original descriptionShow less
Insulin resistance means that the body's cells respond less effectively to insulin, a hormone that regulates blood glucose. This leads to compensatory increases in insulin levels, which can further disrupt hormonal balance and contribute to the clinical features of PMOS.
This study aims to investigate how the bodies of women with PMOS respond dynamically to glucose intake compared with women without PMOS. A standard clinical test, the oral glucose tolerance test (oGTT), will be used. Participants consume a glucose solution, and blood samples are collected before and two hours afterward. This procedure is routinely used in clinical practice.
Women with PMOS will be compared with age- and body mass index (BMI)-matched control participants without PMOS. Blood and urine samples will be analyzed using advanced multi-omics technologies to measure proteins, metabolites, extracellular vesicles, and immune-related signals.
The main objective is to understand how metabolic, hormonal, and immune pathways respond over time to a glucose challenge and whether these responses differ in PMOS. Special attention is given to inter-organ communication and systemic metabolic regulation.
The study includes two visits. The first visit involves health assessments, questionnaires, and body composition measurements. The second visit includes the glucose tolerance test and blood sampling. In total, approximately 100 mL of blood will be collected across both visits.
Participation is voluntary, and participants may withdraw at any time without affecting their medical care. The procedures involve minimal risk and consist of standard clinical methods.
The results of this study may improve understanding of PMOS and contribute to better diagnostic and therapeutic strategies in the future.
The 2 groups in the trial
- PMOS groupTreatment being tested
Woman diagnosed with PMOS, BMI 18.5-39.9 kg/m2
Treatment: Oral Clucose Tolerance Test (oGTT)
- Control groupTreatment being tested
Control participants will be selected to match PMOS group participants with respect to age (±3 years) and BMI (≤ ±2 kg/m²).
Treatment: Oral Clucose Tolerance Test (oGTT)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- METabolic FLEXibility in PMOS
- Plain-language title
- How the body handles sugar in women with polyendocrine metabolic ovarian syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07687264, who can take part
- Record updated
- 7 July 2026